STOCK TITAN

Ventyx Biosciences (VTYX) to be acquired by Eli Lilly in all-cash deal

(Moderate)
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Ventyx Biosciences has agreed to be acquired by Eli Lilly. Under the merger agreement, each share of Ventyx common stock will be converted at the merger’s effective time into the right to receive $14.00 in cash per share, less any tax withholding, and each share of preferred stock will be converted into the right to receive $1,400.00 in cash per share.

Stock options will be cancelled and cashed out based on the $14.00 per share merger price to the extent their exercise price is below that amount; options with exercise prices at or above $14.00 will be cancelled for no payment. Unsettled restricted stock units will be cancelled and replaced with a cash payment based on the $14.00 per share price. Reporting person Raju Mohan beneficially owns 4,387,682 shares (including options), or 6.0% of the company, and has entered into a voting and support agreement to vote his shares in favor of the merger and refrain from transferring them, subject to agreed exceptions.

Positive

  • None.

Negative

  • None.

Insights

All-cash Eli Lilly deal for Ventyx with locked-in support from a 6% holder.

The disclosure describes a definitive agreement for Eli Lilly to acquire Ventyx Biosciences in an all-cash transaction. Common shareholders are to receive $14.00 per share, while preferred shareholders receive $1,400.00 per share, both in cash at the merger effective time, subject to tax withholding. This structure provides a clear cash value per share rather than stock consideration.

Equity incentives are treated in cash: stock options are cancelled and cashed out only to the extent their exercise price is below the $14.00 merger price, with any underwater options terminated without payment, and RSUs are cancelled in exchange for cash using the same per-share value. This concentrates value into cash at closing and eliminates ongoing equity overhang.

The filing also highlights governance mechanics: Raju Mohan, who beneficially owns 4,387,682 shares (including options exercisable within 60 days) representing 6.0% of the class, has entered a voting and support agreement. He has granted Eli Lilly an irrevocable proxy limited to matters related to the merger and agreed to vote his shares in favor of the transaction and against competing actions, while also agreeing not to transfer his subject shares except under specified exceptions, until the earlier of the merger effective time or termination of the merger agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What acquisition involving Ventyx Biosciences (VTYX) is described here?

The document describes an Agreement and Plan of Merger under which a wholly owned subsidiary of Eli Lilly and Company will merge with Ventyx Biosciences, leaving Ventyx as a wholly owned subsidiary of Eli Lilly after the merger becomes effective.

How much will Ventyx Biosciences common shareholders receive per share in the Eli Lilly deal?

At the merger’s effective time, each share of Ventyx common stock issued and outstanding immediately prior to that time will be converted into the right to receive $14.00 in cash per share, without interest and less any applicable tax withholding.

What consideration will Ventyx Biosciences preferred shareholders receive in the merger?

Each share of Ventyx preferred stock issued and outstanding immediately prior to the effective time will be converted into the right to receive $1,400.00 in cash per share, without interest and less any applicable tax withholding.

How are Ventyx Biosciences stock options treated in the Eli Lilly acquisition?

Each outstanding Ventyx stock option (other than purchase rights under the 2021 Employee Stock Purchase Plan) will be cancelled at the effective time. The holder will receive a cash payment equal to the number of shares subject to the option multiplied by the excess of the $14.00 merger consideration over the option’s exercise price, if any. Options with an exercise price equal to or greater than $14.00 will be cancelled for no consideration.

What happens to Ventyx Biosciences restricted stock units (RSUs) in the merger?

Each outstanding Ventyx RSU, whether unvested or vested but not yet settled as of immediately prior to the effective time, will be cancelled. The holder will become entitled to a cash payment equal to the number of shares underlying the RSU multiplied by the $14.00 per-share merger consideration, less any tax withholding.

What is Raju Mohan’s beneficial ownership in Ventyx Biosciences, and how is it composed?

Raju Mohan beneficially owns an aggregate of 4,387,682 shares of Ventyx common stock, representing 6.0% of the class. This includes 2,372,863 shares held directly and 2,014,819 shares issuable upon exercise of stock options that are exercisable within 60 days of January 7, 2026.





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
Items 7, 9 and 11 consist of (i) 2,372,863 shares of common stock held directly by the Reporting Person and (ii) 2,014,819 shares of common stock issuable pursuant to options held directly by the Reporting Person exercisable within 60 days of January 7, 2026. Item 13 is calculated based on the quotient obtained by dividing (a) the aggregate number of shares of common stock beneficially owned by the Reporting Person by (b) the sum of (i) 71,358,638 shares of common stock outstanding as of November 3, 2025, based on information provided by the Issuer and (ii) 2,014,819 shares of common stock issuable pursuant to options held directly by the Reporting Person exercisable within 60 days of January 7, 2026.


SCHEDULE 13D


Raju Mohan
Signature:/s/ Austin Rutherford
Name/Title:Austin Rutherford, as Attorney-in-Fact
Date:01/09/2026